Universe Pharmaceuticals (UPC) Competitors $3.97 0.00 (0.00%) As of 10:34 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock UPC vs. ATXI, BIOR, HEPA, SYRS, BPTSY, KRBP, MYMD, TFFP, VINC, and VRPXShould you be buying Universe Pharmaceuticals stock or one of its competitors? The main competitors of Universe Pharmaceuticals include Avenue Therapeutics (ATXI), Biora Therapeutics (BIOR), Hepion Pharmaceuticals (HEPA), Syros Pharmaceuticals (SYRS), Biophytis (BPTSY), Kiromic BioPharma (KRBP), MyMD Pharmaceuticals (MYMD), TFF Pharmaceuticals (TFFP), Vincerx Pharma (VINC), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "pharmaceutical products" industry. Universe Pharmaceuticals vs. Its Competitors Avenue Therapeutics Biora Therapeutics Hepion Pharmaceuticals Syros Pharmaceuticals Biophytis Kiromic BioPharma MyMD Pharmaceuticals TFF Pharmaceuticals Vincerx Pharma Virpax Pharmaceuticals Universe Pharmaceuticals (NASDAQ:UPC) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, community ranking, analyst recommendations, media sentiment, profitability, institutional ownership and risk. Is UPC or ATXI more profitable? Universe Pharmaceuticals' return on equity of 0.00% beat Avenue Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Universe PharmaceuticalsN/A N/A N/A Avenue Therapeutics N/A -471.57%-296.50% Do institutionals and insiders hold more shares of UPC or ATXI? 0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Comparatively, 1.8% of Avenue Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher valuation & earnings, UPC or ATXI? Universe Pharmaceuticals has higher revenue and earnings than Avenue Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUniverse Pharmaceuticals$23.02M0.01-$8.73MN/AN/AAvenue TherapeuticsN/AN/A-$10.38M$18.350.01 Which has more volatility and risk, UPC or ATXI? Universe Pharmaceuticals has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500. Does the media prefer UPC or ATXI? In the previous week, Universe Pharmaceuticals had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for Universe Pharmaceuticals and 0 mentions for Avenue Therapeutics. Universe Pharmaceuticals' average media sentiment score of 1.00 beat Avenue Therapeutics' score of -0.27 indicating that Universe Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Universe Pharmaceuticals Positive Avenue Therapeutics Neutral Does the MarketBeat Community prefer UPC or ATXI? Avenue Therapeutics received 147 more outperform votes than Universe Pharmaceuticals when rated by MarketBeat users. Likewise, 60.25% of users gave Avenue Therapeutics an outperform vote while only 0.00% of users gave Universe Pharmaceuticals an outperform vote. CompanyUnderperformOutperformUniverse PharmaceuticalsOutperform VotesNo VotesUnderperform Votes1100.00% Avenue TherapeuticsOutperform Votes14760.25% Underperform Votes9739.75% SummaryUniverse Pharmaceuticals beats Avenue Therapeutics on 8 of the 11 factors compared between the two stocks. Get Universe Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for UPC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPC vs. The Competition Export to ExcelMetricUniverse PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$159K$2.45B$5.21B$8.61BDividend YieldN/A1.53%5.32%4.20%P/E RatioN/A9.1025.4319.10Price / Sales0.01537.09426.38157.63Price / CashN/A165.1935.6355.74Price / Book0.005.067.865.09Net Income-$8.73M$37.47M$3.15B$249.14M7 Day Performance-3.41%-2.31%-2.02%-1.14%1 Month PerformanceN/A9.17%4.99%2.95%1 Year PerformanceN/A1.10%34.73%16.04% Universe Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPCUniverse Pharmaceuticals1.3355 of 5 stars$3.97flatN/AN/A$159K$23.02M0.00220Positive NewsATXIAvenue Therapeutics1.9566 of 5 stars$0.21-26.6%N/A-92.7%$663KN/A0.014BIORBiora Therapeutics1.8242 of 5 stars$0.15+6.5%$23.00+15,664.2%-97.8%$660K$892K-0.01120HEPAHepion Pharmaceuticals1.1942 of 5 stars$0.07+18.8%N/A-99.8%$645KN/A-0.0220News CoverageSYRSSyros Pharmaceuticals3.7529 of 5 stars$0.02-7.1%$3.33+14,847.7%-99.6%$598K$386K-0.01120Gap UpBPTSYBiophytisN/A$1.38flatN/A-76.7%$485KN/A0.0030Gap DownKRBPKiromic BioPharmaN/AN/AN/AN/A$330KN/A-0.0660Gap DownHigh Trading VolumeMYMDMyMD PharmaceuticalsN/A$0.14-10.6%N/A-93.5%$325KN/A0.006Gap DownHigh Trading VolumeTFFPTFF PharmaceuticalsN/A$0.07flatN/AN/A$289K-$70.98K-0.0119VINCVincerx Pharma3.6099 of 5 stars$0.06-6.5%$40.00+72,627.3%-99.6%$288KN/A0.0060Positive NewsGap UpVRPXVirpax Pharmaceuticals1.561 of 5 stars$0.23-2.7%$75.00+32,213.7%-98.6%$288KN/A0.007 Related Companies and Tools Related Companies Avenue Therapeutics Alternatives Biora Therapeutics Alternatives Hepion Pharmaceuticals Alternatives Syros Pharmaceuticals Alternatives Biophytis Alternatives Kiromic BioPharma Alternatives MyMD Pharmaceuticals Alternatives TFF Pharmaceuticals Alternatives Vincerx Pharma Alternatives Virpax Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPC) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s End Game Is Going Live -- And It Could Make You a FortuneThe media and the so-called experts have laughed at Elon Musk his entire career. CBS called PayPal “one of ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Universe Pharmaceuticals INC Please log in to your account or sign up in order to add this asset to your watchlist. Share Universe Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy UPC Stock Free UPC Stock Alerts